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Abstract
Background: The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-
resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the
efficacy and toxicity of DTX with or without EMP and to elucidate the significance of DTX and EMP combination
therapy in Japanese EMP-refractory CRPC patients.
Methods: To compare the efficacy and toxicity of DTX and EMP, we divided CRPC patients, who were confirmed
to be resistant to EMP, into the following two groups: group D (n = 28), which included patients treated with DTX
(60 mg/m
2, once in every four weeks) alone, and group DE (n = 33), which included patients treated with a
combination of DTX (60 mg/m
2, once in every four weeks) and EMP (twice daily oral administration at 280 mg).
Results: Prostate specific antigen (PSA) response (> 50% decline in PSA) was observed in six patients (21%) in
group D and eight patients (24%) in group DE. The median time to progression (TTP) was 12.0 months and 6.2
months and the median overall survival (OS) was 26.4 months and 24.3 months in group D and DE, respectively.
There was no statistical difference between the two groups in terms of PSA response, TTP, and OS. The incidence
of adverse events of grade 3/4 was low in both the groups, and there was no statistical difference between the
two groups.
Conclusions: Although treatment with DTX at 60 mg/m
2 was effective and highly tolerated in EMP-refractory
Japanese CRPC patients, the DTX and EMP combination therapy might not exhibit any survival benefit for CRPC
patients.
Background
The efficacy of docetaxel (DTX) in castration-resistant
prostate cancer (CRPC) patients was shown in two clini-
cal trials of TAX 327 [1] and SWOG 9916 [2] in 2004.
Thereafter, DTX-based therapies have been used world-
wide for treating CRPC patients. TAX 327 reported a
median overall survival (OS) of 18.9 months with
administration of DTX every three weeks, and SWOG
9916 reported a median OS of 17.5 months with DTX
and estramustine phosphate (EMP) combination therapy
every three weeks. While these results showed that DTX
was more effective than mitoxantrone, they also raised
other questions about whether addition of EMP to DTX
was effective for CRPC patients. To clarify this point,
several clinical trials and one meta-analysis have been
performed thus far. While there have been some reports
describing the usefulness of DTX and EMP combination
therapy [3-5], other reports suggest that the combina-
tion treatment is not useful [6]. A preclinical report
showed that addition of EMP did not enhance the effi-
cacy of DTX [7], while other preclinical studies con-
firmed that EMP in combination with DTX exerted
beneficial effects in prostate cancer [8,9]. Since the
views on the efficacy of DTX and EMP combination
therapy are controversial, it is important to determine
clinically whether or not EMP enhances the efficacy of
DTX.
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trials described above, however, CRPC patients pre-
treated with EMP were excluded in SWOG 9916, while
both patients treated with and without EMP were
enrolled in the clinical trials described above
4-6.S i n c e
patients entered in these previous clinical trials were
EMP-naive patients or the mixture of EMP-naive and
refractory patients, we focused on the efficacy of DTX
by the addition of EMP in EMP-refractory CRPC
patients in order to examine the modulatory effect of
EMP on DTX in clinical setting.
In the present study, we retrospectively compared the
efficacy and toxicity of DTX treatment with and without
EMP in Japanese EMP-refractory CRPC patients in
order to elucidate the significance of the addition of
EMP to DTX therapy.
Methods
Subjects
Between July 2003 and October 2010, 90 CRPC patients
were pathologically diagnosed with adenocarcinoma of
the prostate and treated with DTX at our institution.
From this group, 61 CRPC patients who were treated
with EMP monotherapy, then confirmed to be resistant
to EMP, and received two or more courses of DTX
therapy were included in the present analysis. These
EMP-refractory CRPC patients were divided into two
groups as follows: group D consisting of 28 patients
who were treated with DTX without EMP and group
DE consisting of 33 patients treated with DTX and EMP
combination. The reasons why EMP was not concomi-
tantly administered in group D included adverse events
in 16 patients (57%) and the patient request in 12
patients (43%). DTX therapy was initiated in patients
resistant to androgen deprivation therapy, which uses
luteinizing hormone-releasing hormone (LHRH) analo-
gue and antiandrogen. Patients with antiandrogen with-
drawal syndrome were excluded from the study. The
inclusion criteria were Eastern Cooperative Oncology
Group (ECOG) performance status (PS) of two or lower,
white blood cell (WBC) count ≥1500/mm
3, hemoglobin
(Hb) ≥8 g/dL, platelet count ≥100000/mm
3, total biliru-
bin ≤ upper limit of normal (ULN), and aspartate ami-
notransferase (AST) and alanine aminotransferase (ALT)
≤2.5 × ULN.
The patient characteristics by group are shown in
Table 1. There was no statistical difference in all para-
meters between both the groups. The median observa-
tion period was 19.5 months (range; 3.0-60.9 months).
The median number of DTX treatment course was four
in group D and five in group DE. This study was
approved by the institutional review board of Jichi Med-
ical University and written informed consent was
obtained from all patients.
Treatment
We used a modified version of the regimen used in
SWOG 9916 [2] as the treatment protocol. Briefly, DTX
60 mg/m
2 was administered by intravenous drip infu-
sion for one hour on day one once every four weeks.
Further, eight mg of dexamethasone was administered
by intravenous drip infusion as premedication before
and after treatment with DTX. The treatment course
was repeated every four weeks. In group D, DTX alone
was administered after confirming the resistance to
EMP. Meanwhile, in group DE, DTX and EMP equiva-
lent to the amount administered before DTX therapy
was administered after confirming the resistance to
EMP. Although 280 mg EMP twice daily was orally
administered every day, dose reduction up to 280 mg/
day was allowed according to the degree of adverse
events. The treatment was continued until progression
of disease was observed, and it was stopped after the
occurrence of adverse events which made it impossible
to continue the treatment or on patient request. Pro-
gression of disease was defined as biological progression
characterized by the increase in evaluable lesions
observed on imaging test or continuous elevation of
serum PSA on at least three consecutive measurements.
At the initiation of treatment and before each cycle,
medical history of the patient was taken and physical
examination, PS evaluation, and hematological examina-
tion (blood count, biochemistry, and PSA) were per-
formed at least once every four weeks. Computed
tomography (CT) and bone scintigraphy were performed
at least once every 16 weeks.
Outcomes
Primary endpoint was PSA response. According to the
recommendations of Prostate Cancer Clinical Trial
Working Group [10], the decreasing rate of PSA of each
patient is shown in the waterfall plot. The decreasing
rate of PSA was obtained from the value determined
just before the initiation of treatment with DTX and the
lowest value of PSA during treatment. Patients with a
PSA decrease rate of 50% or more were defined as PSA
responders and those with a rate of 0% or less were
PSA nonresponders.
Secondary endpoints were time to progression (TTP)
of PSA, OS, and toxicity. TTP was defined as the period
from the initiation of treatment to PSA progression.
PSA progression was defined as a 25% or greater
increase and an absolute increase of 2 ng/mL or more
from the nadir, which was confirmed by a second value
obtained three or more weeks later. OS was defined as
the period from the initiation of treatment to death.
When patients were lost to follow-up, OS was consid-
ered up to the last day on which the patient survival
was confirmed.
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sification by National Cancer Institute Common Toxi-
city Criteria (NCI-CTC), version 4.
Statistics
Mann-Whitney U test or chi-square test was used for
comparing clinical and pathological data, PSA response,
and adverse events. TTP and OS were obtained by using
Kaplan-Meier method and compared using log-rank test.
Multivariate analysis was performed by using Cox pro-
portional-hazard analysis for the identification of prog-
nostic factors. Continuous data were divided into two
groups according to median value. P value of less than
0.05 was judged as statistically significant.
Results
Efficacy
PSA response by group is shown in a waterfall plot (Figure
1). Six patients (21%) in group D and eight patients (24%)
in group DE were PSA responders and 10 patients (36%)
in group D and 11 patients (33%) in group DE were PSA
nonresponders. There was no statistical difference in PSA
response between these two groups (p = 0.962).
The median TTP was 12.0 months (range; 1.5-54.3
months) in group D and 6.2 months (range; 2.4-39.2
months) in group DE (Figure 2A); further, the median
OS was 26.4 months (range; 3.9-60.9 months) in group D
and 24.3 months (range; 3.0-51.8 months) in group DE
(Figure 2B). There were no statistical differences in med-
ian TTP and OS between these two groups (TTP, p =
0.113; OS, p = 0.853). Eight patients (29%) in group D
and 19 patients (58%) in group DE died of cancer. The
reasons for discontinuation were progression of disease
in 18 patients (64%) in group D and 22 patients (67%) in
group DE and the occurrence of adverse events in three
patients (11%) in group D and one patient (3%) in group
D E .C u r r e n t l y ,f o u rp a t i e n t s( 1 4 % )i ng r o u pDa n ds i x
patients (18%) in group DE are continuing the treatment.
Subgroup analysis
Univariate analysis using log-rank test revealed a signifi-
cant association between OS and five factors (PSA at
Table 1 Patients’ characteristics
Docetaxel with estramustine
(n = 33)
Docetaxel without estramustine
(n = 28)
p value*
Age (years), median (range) 67 (55-88) 72 (50-82) 0.062
PSA at PCa diagnosis (ng/ml), median(range) 124.1 (10.3-4116.0) 102.1 (4.7-19523.1) 0.452
PSA at baseline (ng/ml), median(range) 17.1 (0.6-1053.0) 11.4 (0.8-618.4) 0.633
Time from diagnosis to this chemothrapy (months), median(range) 34 (4-176) 37 (7-113) 0.492
ECOG performance status, n (%) 0.299
0 19 (58) 12 (43)
1 9 (27) 13 (46)
2 5 (15) 3 (11)
Gleason score, n (%) 0.517
< 6 2 (6) 2 (7)
7 9 (27) 4 (14)
> 8 20 (61) 19 (68)
unknown 2 (6) 3 (11)
Metastatic site, n (%)
Bone 17 (52) 16 (57) 0.797
Lymph nodes 10 (30) 11 (39) 0.590
Liver 0 (0) 1 (4) 0.459
Lung 3 (9) 0 (0) 0.243
None 12 (36) 7 (25) 0.080
Prior treatment, n (%)
MAB 33 (100) 28 (100) ne
Estramustine 33 (100) 28 (100) ne
Radical Prostatectomy 2 (6) 1 (4) 1.000
Radiation Therapy 4 (12) 3 (11) 1.000
Dexamethasone 8 (24) 11 (39) 0.270
Other Chemotherapy 6 (18) 8 (29) 0.375
No. of cycles, median (range) 5 (2-32) 4 (2-27) 0.382
* by Mann-Whitney U test and chi-square test, PSA, prostate-specific antigen; PCa, Prostate Cancer; CRPC, Castration Resistant Prostate Cancer; ECOG, Eastern
Cooperative Oncology Group; MAB, Maximum Androgen Blockage; ne, not evaluable
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to DTX chemotherapy, bone metastasis, and the number
of DTX cycles). These five factors were used in multi-
variate analysis. A PSA value > 12.8 ng/mL at baseline
indicated significantly worse prognosis, and 35 months
or more period from the diagnosis to DTX chemother-
apy and five or more cycles of DTX suggested signifi-
cantly better prognosis. The presence or absence of
EMP with DTX was not a prognostic factor (Table 2).
Multivariate analysis using six factors, which included
the five above-mentioned factors and treatment factor
(group D vs group DE), revealed the same results as
shown in Table 2, indicating that addition of EMP to
DTX is not associated with prognosis (data not shown).
Toxicity
Adverse events are shown in Table 3. There was no sta-
tistical difference between the two groups based on the
incidence of grade 3/4 adverse events. The most fre-
quent adverse events were neutropenia (n = 19, 68%) in
group D and leukopenia (n = 15, 45%) in group DE.
The most frequent grade 3/4 adverse event was neutro-
penia in the both groups; 14 patients (50%) in group D
and 11 patients (33%) in group DE had neutropenia.
Although there were no significant differences in the
incidence of leukopenia and neutropenia between the
two groups, these effects were less common in group
DE than in group D. Further, grade 2 thromboembolism
in one patient and interstitial pneumonia in one patient
were observed in group DE; however, there was no
treatment-related death in any group. In addition, gas-
trointestinal symptoms (anorexia, nausea, and diarrhea),
fatigue, and alopecia were frequently observed in the
both the groups. Grade 3 allergic reaction was observed
in one patient in group DE and taste disorder was
observed in two patients (one patient in group D and
one patient in group DE).
Discussion
The significance of addition of EMP to DTX therapy in
CRPC patients is still controversial in clinical trials [3-6]
as well as preclinical studies [7-9]. Therefore, it is rea-
sonable to compare the clinical efficacy of DTX + EMP
combination with DTX alone in EMP-refractory CRPC
patients in order to elucidate the significance of addition
of EMP to DTX therapy. Present retrospective study
showed, for the first time, that there were no significant
A)
B)
Figure 1 Waterfall plots of% change in PSA after treatment by
docetaxel without estramustine (n = 28; A) and with
estramustine (n = 33; B).
A)
B)
Figure 2 Time to PSA progression (A) and overall survival (B)
in patients treated by docetaxel with or without estramustine.
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Univariate Multivariate
parameter category n Hazard ratio 95%CI p value Hazard ratio 95%CI p value
Treatment D 28 1.000 0.853
DE 33 0.934 0.454 1.923
Age (years) ≦70 30 1.000 0.549
> 70 31 0.808 0.401 1.628
Gleason Score ≦7 17 1.000 0.259
> 8 39 1.558 0.718 3.381
PSA at PCa diagnosis (ng/ml) ≦113 31 1.000 0.940
> 113 30 1.027 0.520 2.025
PSA at baseline (ng/ml) ≦12.8 31 1.000 < 0.001 1.000 0.017
> 12.8 30 4.903 2.181 11.024 3.605 1.262 10.296
ECOG performance status ≦1 53 1.000 < 0.001 1.000 0.218
2 8 5.567 2.366 13.098 1.803 0.706 4.605
Time from diagnosis to this chemothrapy (months) ≦35 31 1.000 0.003 1.000 0.015
> 35 30 0.351 0.172 0.715 0.286 0.104 0.782
Bone metastasis no 28 1.000 0.014 1.000 0.419
yes 33 2.383 1.165 4.873 0.646 0.224 1.862
No. of Docetaxel cycles < 5 28 1.000 < 0.001 1.000 < 0.001
<5 33 0.213 0.100 0.452 0.209 0.093 0.472
Hemoglobin (g/dl) ≦12.0 33 1.000 0.120
> 12.0 28 0.580 0.289 1.163
CI, confidence interval; D, Docetaxel without estramustine; DE, Docetaxel with estramustine; PSA, prostate-specific antigen; PCa, Prostate Cancer; ECOG, Eastern
Cooperative Oncology Group; CRPC, Castration Resistant Prostate Cancer
Table 3 Acute adverse events according to NCI-CTC
Docetaxel with estramustine Docetaxel without estramustine
(n = 33) (n = 28)
Any grade* Grade3-4 Any grade Grade3-4 p value**
n%n%n % n %
Leukopenia 15 45 7 21 18 64 11 39 0.123
Neutropenia 13 39 11 33 19 68 14 50 0.187
Febrile neutropenia 00130 0 0 00.353
Anemia 9 27 1 3 5 18 2 7 0.443
Thrombocytopenia 00000 0 0 0 n e
Fatigue 10 30 0 0 10 36 0 0 ne
Anorexia 10 30 0 0 10 36 1 4 0.274
Nausea 13 39 2 6 10 36 0 0 0.185
Diarrhea 4 12 0 0 2 7 0 0 ne
Taste alteration 13001 4 0 0 n e
Dizziness 39002 7 0 0 n e
Flushing 26000 0 0 0 n e
Edema 13002 7 0 0 n e
AST/ALT 13000 0 0 0 n e
Allergic reaction 13131 4 0 00.353
Pulmonary fibrosis 13130 0 0 00.353
Hair loss 14 42 0 0 12 43 0 0 ne
Mood alteration 13000 0 0 0 n e
Neuropathy 13001 4 0 0 n e
Thromboembolic event 13000 0 0 0 n e
* Grade by National Cancer Institute-Common Toxicity Criteria; **indicates the difference of the rate of grade 3-4 adverse events between two regimens by chi-
square test; ne, not evaluable
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events between group D and group DE in EMP-refrac-
tory CRPC patients, suggesting that addition of EMP to
DTX therapy had no survival benefit.
The PSA response (> 50% decline in PSA) in SWOG
9916 [2] was 50%. However, the PSA response in this
study was low; only 21% patients in group D and 24%
patients in group DE responded to treatment with 60
mg/m
2 DTX, which was similar to the regimen of
SWOG 9916. Our result is consistent with that of
another study in which patients who had been treated
with EMP showed a lower PSA response as compared
to patients without a history of EMP treatment [11],
suggesting that treatment with EMP before DTX treat-
ment decreases the PSA response. However, the median
O Si ng r o u pDw a s2 6m o n t h sa n dt h a ti ng r o u pD E
was 24 months. Further, these median OS are not only
greater than that of nine months after treatment with
55 mg/m
2 DTX [12] or that of 18 months after treat-
ment with 60 mg/m
2 DTX in SWOG 9916 but also con-
sistent with the 15-27 months median OS obtained after
treatment with 70-75 mg/m
2 DTX [1,4-6,13,14]. The
median OS of 24 months or more achieved in this study
was considered to be due to the initiation of DTX ther-
apy with low PSA value as compared with that obtained
in the previous reports [1,4-6,13,14], because multivari-
ate analysis performed in this study and the report by
Bamias et al. [15] demonstrated that OS prolonged
when PSA was low at the initiation of DTX therapy.
Since the adverse events observed in this study were
well tolerated, treatment with 60 mg/m
2 DTX seems to
be effective and safe even in EMP-refractory CRPC
patients. In recent years, several novel agents such as
abiraterone [16], sipuleucel-T [17] and MDV3100 [18]
have been developed and showed significant clinical effi-
cacy against CRPC. Treatment with these agents would
provide the survival benefit for CRPC patients.
Regarding adverse events in TAX 327 and SWOG
9916, the incidences of grade 3/4 neutropenia were
32% and 13% in TAX 327 [1] (DTX, 75 mg/m
2)a n d
SWOG 9916 [2] (DTX, 60 mg/m
2), respectively.
Further, the incidence of grade 3/4 neutropenia in
clinical trials performed in Japan was 93% and 33%
after treatment with 70 mg/m
2 [19] and 55 mg/m
2
DTX [12], respectively, indicating high incidences of
DTX toxicity. In addition, the incidence of neutropenia
after 60 mg/m
2 D T Xt r e a t m e n tw a s8 6 %i nac l i n i c a l
study on Japanese pancreatic cancer patients [20], sug-
gesting that the incidence of neutropenia is high
among Japanese patients. Although the sample size of
our study was small, the incidence of grade 3/4 neu-
tropenia was 50% and 33% in group D and DE, respec-
tively, which were higher as compared to the values
reported in SWOG 9916 using 60 mg/m
2 DTX.
However, no incidence of death or severe complica-
tions suggested that our treatment was well tolerated.
Furthermore, grade 2 thromboembolism was observed
in one patient (3%) of group DE. Since EMP increases
the incidence of thromboembolism [2,3,6], it should be
used with caution. The reason why the incidence of
adverse events was not significant between group D
and DE might be due to the means of treatment
assignment. Namely, two-thirds of patients with
adverse events by EMP monotherapy and those with-
out them were classified in group D and DE, respec-
tively. Although addition of EMP to DTX therapy
might not show any survival benefit in CRPC patients,
it was of interest that addition of EMP to DTX therapy
lowered the incidence of grade 3/4 neutropenia (50%
i ng r o u pDa n d3 3 %i ng r o u pD E ) ,t h o u g hn o tb ya
significant extent. Meta-analysis [3] of chemotherapy
combined with EMP showed a significantly low inci-
dence of neutropenia due to concomitant use of EMP
in the chemothrapy. In addition, treatment with EMP
showed increase in the leukocyte count in patients
with hormone-naïve prostate cancer [21] or CRPC
[22]. Taken together, it is suggested that EMP
increases the leukocyte count leading to the myelopro-
tection in the chemotherapy, albeit under limited con-
ditions; hence, the significance of addition of EMP to
DTX therapy may be attributed to the myeloprotection
rather than the survival benefit. Further studies are
required to clarify this point.
Multivariate analysis performed in this study revealed
that PSA at baseline, time from diagnosis to DTX che-
motherapy and the number of DTX cycles were related
to the prognosis. Although these factors were statisti-
cally significant, the definitive conclusions cannot be
drawn because of the small number of death events
observed in this study. These factors have been reported
as prognostic factors in other studies [11,15,23,24];
hence, DTX treatment should be introduced when PSA
values are low and continued for as long as possible.
However, addition of EMP did not serve as a prognostic
factor.
This study has some limitations; it is a retrospective
study with a small sample size and not a randomized
clinical trial. However, it was concluded that addition of
EMP to DTX therapy might not show any survival bene-
fit in EMP-refractory CRPC patients although treatment
with 60 mg/m
2 DTX had the OS and toxicity profiles
comparable to those in TAX 327 and SWOG 9916.
Further studies would be needed to elucidate the signifi-
cance of addition of EMP to DTX therapy.
Conclusions
Although treatment with DTX at 60 mg/m
2 was effec-
tive and highly tolerated in EMP-refractory Japanese
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not show any survival benefit in CRPC patients.
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